Literature DB >> 3553525

The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans.

C A Hitchcock, K J Barrett-Bee, N J Russell.   

Abstract

Candida albicans 6.4, which is resistant to both polyene and azole groups of antifungal antibiotics, has a larger lipid content and lower polar lipid to neutral lipid ratio compared with other strains that are sensitive or resistant only to azoles. C. albicans 6.4 contains a relatively greater proportion of triacylglycerol in its neutral lipid in the exponential phase of batch culture compared with other strains, but, unlike them, does not accumulate triacylglycerols or any other stored lipid in the stationary phase. Like other strains, in C. albicans 6.4 the major phospholipids are phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol, but sphingomyelin is absent; the major fatty acids are palmitic, palmitoleic, oleic and linoleic acids. In common with other C. albicans strains, strain 6.4 contains non-specific (lyso)phospholipase activity. The main distinctive feature of the lipid composition of C. albicans 6.4 is the absence of ergosterol, which is replaced by methylated sterol; mainly lanosterol, 24-methylene-24,25-dihydrolanosterol and 4-methylergostadiene-3-ol. It is suggested that the altered membrane sterol pattern provides a common basis for the double resistance by preventing polyene binding and reducing azole permeability.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3553525     DOI: 10.1080/02681218780000041

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN: 0268-1218


  25 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

Review 2.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 3.  Amphotericin B: current understanding of mechanisms of action.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

4.  Reversible fluconazole resistance in Candida albicans: a potential in vitro model.

Authors:  H M Calvet; M R Yeaman; S G Filler
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  Phospholipid biosynthesis in Candida albicans: regulation by the precursors inositol and choline.

Authors:  L S Klig; L Friedli; E Schmid
Journal:  J Bacteriol       Date:  1990-08       Impact factor: 3.490

6.  Azole susceptibility and hyphal formation in a cytochrome P-450-deficient mutant of Candida albicans.

Authors:  N D Lees; M C Broughton; D Sanglard; M Bard
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

7.  Recombinagenicity of caffeine for Candida albicans.

Authors:  A Sarachek; L A Henderson
Journal:  Mycopathologia       Date:  1990-05       Impact factor: 2.574

8.  Proton-pumping-ATPase-targeted antifungal activity of a novel conjugated styryl ketone.

Authors:  E K Manavathu; J R Dimmock; S C Vashishtha; P H Chandrasekar
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

9.  In vitro activity of a new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.

Authors:  F Barchiesi; A L Colombo; D A McGough; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 10.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors:  B D Alexander; J R Perfect
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.